Skip to main content
Data from the American Rheumatology Network (2014–2021) shows that among 15182 new TNFi initiations, only 45% had a dz

Dr. John Cush RheumNow

2 years 7 months ago
Data from the American Rheumatology Network (2014–2021) shows that among 15182 new TNFi initiations, only 45% had a dz activity measure (CDAI/RAPID3); and of these, only 47% had a TJC, SJC or pain score. Can you treat HTN without measuring BP? https://t.co/SsnF7Taky1 https://t.co/LN72IAWs8n
Tic-Borne Disorders Causing Chronic Arthritis?

Findings from a population based cross-sectional study suggests that wh

Dr. John Cush RheumNow

2 years 7 months ago
Tic-Borne Disorders Causing Chronic Arthritis? Findings from a population based cross-sectional study suggests that while up to 20% of patients have antibodies to tick-borne exposures, only a minority reported musculoskeletal symptoms. https://t.co/FWhCl3v8oH https://t.co/NDgvKYva11
The original randomized controlled, prospective MAINRITSAN study of 115 patients (87 with granulomatosis with polyangiitis, 23 with microscopic polyangiitis, and 5 with renal-limited ANCA-associated vasculitis [AAV]) demonstrated superiority of rituximab (RTX) over azathioprine (AZA) for maintenance of remission at 22 months in ANCA-associated vasculitis patients after CYC remission induction.
IL-17 pathway as a target in giant cell arteritis - full read review of pathogenic role of IL-17 and Th17 cells, in #GC

Dr. John Cush RheumNow

2 years 7 months ago
IL-17 pathway as a target in giant cell arteritis - full read review of pathogenic role of IL-17 and Th17 cells, in #GCA; backed up by the phase II proof-of-principle TiTAIN study showing potential efficacy of secukinumab in GCA pts https://t.co/2qX1F6ZP6J https://t.co/zoknjDgMQy
Excited to be talking at https://t.co/hposbnLVdD!!

As usual, @RheumNow screen-grabbed me at an opportune moment 🤣?

Mike Putman EBRheum

2 years 7 months ago
Excited to be talking at https://t.co/hposbnLVdD!! As usual, @RheumNow screen-grabbed me at an opportune moment 🤣😆 Highly recommend the conference; register live/online at the link above! https://t.co/XewJXRASi8
2023 EULAR Non-pharmacological Management of Hip and Knee Osteoarthritis: 2023 update

EULAR has published the 2023 upd

Dr. John Cush RheumNow

2 years 7 months ago
2023 EULAR Non-pharmacological Management of Hip and Knee Osteoarthritis: 2023 update EULAR has published the 2023 updated recommendations for the optimal non-pharmacological management of hip and knee osteoarthritis (OA). https://t.co/B7hE9jaGuo https://t.co/WCZ0VNcdKR
Mayo study shows multimorbidity in RA increases serious infx (SI) risk; 911 RA pts (56 yrs, 2/3 seropositive) 17% had SI

Dr. John Cush RheumNow

2 years 7 months ago
Mayo study shows multimorbidity in RA increases serious infx (SI) risk; 911 RA pts (56 yrs, 2/3 seropositive) 17% had SI (3.9/100PY). Hi risk morbidities(bipolar Dz, CKD, COPD,, chr skin ulcers) were assoc w/ 3 to 5-fold increased SI risk https://t.co/qorKp96KTm https://t.co/o5FaMKMskA
Japanese retrospective study compared RA pts on JAK inhib vs bDMARDs (n=62 ea) having orthopedic surgery; JAKi- pts had

Dr. John Cush RheumNow

2 years 7 months ago

Japanese retrospective study compared RA pts on JAK inhib vs bDMARDs (n=62 ea) having orthopedic surgery; JAKi- pts had more postoperative flares (29% v 12%, P=.01), esp if JAKi held >11d (p.04). No diff in other postop complications https://t.co/E2fJS3N7KU https://t.co/4H00TgXVr2

What do you know about monogenic and polygenic autoinflammatory diseases? Join Drs Liebowitz and Mehta as they review t

Dr. John Cush RheumNow

2 years 7 months ago

What do you know about monogenic and polygenic autoinflammatory diseases? Join Drs Liebowitz and Mehta as they review the challenges of these conditions. https://t.co/TXJbpD3yB4 https://t.co/QGDaZdqrqz

Retrospective cohort compared 6147 new PsA pts vs 23,999 contros PsA. The uveitis risk was significantly higher in PsA (

Dr. John Cush RheumNow

2 years 7 months ago
Retrospective cohort compared 6147 new PsA pts vs 23,999 contros PsA. The uveitis risk was significantly higher in PsA (adj HR 2.38). Uveitis risk in PsA higher with prior uveitis (adj OR 136.4) and etanercept Rx (aOR 2.57). 106/107 Rx w/ topical steroids https://t.co/JSQ4fXpXja https://t.co/kl2JWcLBih
Prior authorizations and paperwork are killing medical providers; the good news is that a new CMS rule may lessen the burden. The Centers for Medicare & Medicaid Services (CMS) has announced that they have finalized the CMS Interoperability and Prior Authorization Final Rule, designed to improve prior authorization processes and reduce burden on patients, providers, and payers, with a resultant $15 billion of estimated savings over ten
Fertility and Rheumatoid Onset
  • MedPage Today
British women whose capability of bearing children either started late or ended early -- naturally or otherwise -- were at increased risk for developing rheumatoid arthritis (RA), compared with women with earlier menarche or later menopause, researchers found.
×